Evox To Raise Cash In 2018 For Novel Exosome Platform
Executive Summary
Emerging Company Profile: Evox Therapeutics – a privately held, Oxford-based biotechnology company developing a new class of biotherapeutics called exosomes – is using its technology to improve the delivery of validated therapies, particularly targeting central nervous system and neuromuscular conditions.
You may also be interested in...
Novo's €2.6bn Ablynx Bid Opens The Door For Better Offers
Gilead, Amgen and AbbVie are names that could join the fray should a bidding war start for Nanobody drug developer Ablynx, which has rebuffed two takeover offers from Novo Nordisk.
Effective Integration Is The Key To BD Success For Ipsen
At the 2023 BIO-Europe conference, In Vivo sat down with Ipsen’s EVP and chief business officer, Philippe Lopes-Fernandes, to discuss the company’s business development strategy and future goals.
Scrip 100: By The Numbers
Pfizer dominated the Scrip 100 rankings of the top pharmaceutical companies in the world based on full year 2022 pharmaceutical sales, driven by its COVID-19 success.